AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 11 - (NewsRx.com & NewsRx.net) -- Despite the problems that have occurred in vaccine trials for Alzheimer disease, research should continue.
"Active or passive immunization against the beta-amyloid peptide (A-beta) has been proposed as a method for preventing and/or treating Alzheimer's disease (AD). In addition to lowering brain A-beta and amyloid burden in transgenic mouse models of AD, a beneficial effect of immunization on previously characterized memory impairment(s) has also been reported in these mice," researchers in the United States report.
"Whether these preclinical data will predict efficacy in AD patients remains to be seen," said Jean-Cosme Dodart and collaborators at Eli Lilly and Company. "A clinical trial of active immunization (vaccination) was halted, owing to a serious adverse event (meningoencephalitis), raising questions about the safety of this approach. Two recent reports suggest that immunotherapy-based approaches to treating and preventing AD will require careful antigen and ...
Source: HighBeam Research, Vaccine research for Alzheimer disease should continue despite...